Asthma ⭐

asthma · society: GINA · high-yield

← back to Pulmonary & Critical Care

Summary

GINA 2026 is the annual update of the Global Strategy for Asthma Management and Prevention, covering diagnosis, assessment, pharmacologic and non-pharmacologic management, exacerbations, severe asthma, and prevention across all ages. Key 2026 changes include four new exacerbation flowcharts with revised lower oxygen saturation thresholds (≥92%) and more conservative SABA dosing; addition of as-needed ICS-formoterol (AIR) and ICS-SABA options for children 6–11 years (CARE study) and adults (BATURA study); new biologics depemokimab (long-acting anti-IL5, q26-weekly) and biosimilar omalizumab-igec; expanded Step 5 LAMA options including budesonide-formoterol-glycopyrronium; and retention of the ≥12% and ≥200 mL FEV₁ criterion for bronchodilator responsiveness. Track 1 (ICS-formoterol as reliever, with or without maintenance) remains the preferred approach for adults/adolescents.

Current guideline: GINA 2026 — Global Strategy for Asthma Management and Prevention · download Anki sub-deck

Versions